• Users Online: 804
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2021  |  Volume : 12  |  Issue : 7  |  Page : 24-30

Updates on management of leprosy in the context of COVID-19 pandemic: Recommendations by IADVL SIG Leprosy


1 Department of Dermatology, Venereology and Leprology, All India Institute of Medial Sciences, Jodhpur, Rajasthan, India
2 Department of Dermatology, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India
3 Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
4 Institute for Specialized Services in Leprosy (INSSIL), Nireekshana ACET, Hyderabad, Telangana, India
5 Department of Dermatology, All India Institute of Medial Sciences, Patna, Bihar, India
6 Department of Dermatology, Smt NHL Municipal Medical College, Ahmedabad, Gujarat, India
7 Department of Dermatology, King George's Medical University, Lucknow, Uttar Pradesh, India
8 Department of Dermatology, Christian Medical College, Vellore, Tamil Nadu, India
9 Department of Dermatology, AIIMS, Raipur, Chhattisgarh, India
10 Department of Dermatology, SVS Medical College, Mahbubnagar, Telangana, India
11 Department of Dermatology, JSS Medical College, Mysore, Karnataka, India
12 Department of Dermatology, INHS Asvini, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Tarun Narang
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/idoj.idoj_513_21

Rights and Permissions

The Special Interest Group (SIG) on leprosy thought it to be prudent to revisit its previous practice recommendations through this update. During this period, the pandemic course shifted to a 'second wave' riding on the 'delta variant'. While the number of cases increased manifold, so did the research on all aspects of the disease. Introduction of vaccination and data from various drug trials have an impact on current best practices on management of diseases including leprosy. The beneficial results of using steroids in management of COVID-19, gives elbow room regarding its usage in conditions like lepra reactions. On the other hand, the increase in cases of Mucormycosis again underlines applying due caution while recommending immunosuppressants to a patient already suffering from COVID-19. This recommendation update from SIG leprosy reflects current understanding about managing leprosy while the dynamic pandemic continues with its ebbs and flows.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed190    
    Printed0    
    Emailed0    
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal